Boston Scientific to pay $431M in stent patent trial

Minneapolis / St. Paul Business Journal - by Carissa Wyant Staff Writer

Boston Scientific said Tuesday that it would pay $431 million to settle a patent infringement suit involving drug-coated stents made by the medical device company.

Natick, Mass.-based Boston Scientific (NYSE: BSX) said that a jury in Marshall, Texas decided the company's Taxus Express and Taxus Liberte stents infringed on a patent obtained by Dr. Bruce Saffran. Boston Scientific has operations in Maple Grove and Arden Hills.

The company said in a press release that it will seek to overturn the verdict, and if that measure fails, it will appeal the decision.